---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-020059"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T19:54:30.634683+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Femasys reports Q1 net income of $846K; sales up 24.5%; cash sufficient into Q3 2026

## Summary
- Net income $846,100 ($0.00 per diluted share) vs net loss $5.9M ($0.23 loss) in prior year; net income includes $5.2M in gains from fair value changes.
- Sales rose 24.5% to $424,889, driven by FemBloc sales; R&D expenses down 55.9% to $1.31M.
- Cash $5.4M as of March 31; company expects funding into Q3 2026 based on current operating plan.
- Advanced FemaSeed Complete commercialization; initiated FINALE pivotal trial for FemBloc non-surgical birth control.
- Appointed John Canning as COO; added Kenneth D. Eichenbaum to board; MDSAP certification for FemBloc.

## SEC filing metadata
- accession: 0001140361-26-020059
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036126020059/0001140361-26-020059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036126020059/ef20072749_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-020059
- JSON: https://secwatch.observer/filing/0001140361-26-020059.json
- Plain text: https://secwatch.observer/filing/0001140361-26-020059.txt

## Source-grounded claims
- claim_id: d932efe1b281e20a4539a246c8935b780b6c678d
  claim: FEMASYS INC reported quarter ended March 31, 2026 results: revenue $424,889, net income $846,100, or $0.00 per basic and diluted share, EPS $0.00 per basic and diluted share.
  evidence_excerpt: addressing critical unmet needs with safe, technologically advanced products.” Financial Results for Quarter Ended March 31, 2026 • Sales increased by $83,625, or 24.5%, to $424,889 in 2026 from $341,264 in 2025, primarily due to sales of FemBloc. • Research and development expenses decreased by $1,659,071, or 55.9%, to $1,309,401 in 2026 compared to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339005/000114036126020059/0001140361-26-020059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.